Chromosomal evolution of Escherichia coli for the efficient production of lycopene

BMC Biotechnology

Research Article

Zhi-Ming Weng¹  Yan-Yan Cui¹  Shang-Guang Chen¹  Jian-Zhong Liu¹  Yun-Yan Chen¹  Hong-Jie Shen¹  Ming Zhao² 

[1]Biotechnology Research Center and MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Life Science, Sun Yat-Sen University, 510275, Guangzhou, P. R. China

[2]Medical Imaging Center, Cancer Center and State Key Laboratory of Oncology in South China, Sun Yat-Sen University, 510060, Guangzhou, P. R. China

关键词: Lycopene;    Escherichia coli;    Chemically induced chromosomal evolution;    Metabolic engineering;   

DOI  :  10.1186/1472-6750-13-6

 received in 2012-08-26, accepted in 2013-01-24,  发布年份 2013

来源: Springer

【 摘 要 】

BackgroundPlasmid-based overexpression of genes has been the principal strategy for metabolic engineering. However, for biotechnological applications, plasmid-based expression systems are not suitable because of genetic instability, and the requirement for constant selective pressure to ensure plasmid maintenance.ResultsTo overcome these drawbacks, we constructed an Escherichia coli lycopene production strain that does not carry a plasmid or an antibiotic marker. This was achieved using triclosan-induced chromosomal evolution, a high gene copy expression system. The engineered strain demonstrated high genetic stability in the absence of the selective agent during fermentation. The replacement of native appY promoter with a T5 promoter, and the deletion of the iclR gene in E. coli CBW 12241 further improved lycopene production. The resulting strain, E. coli CBW 12241(ΔiclR, PT5-appY), produced lycopene at 33.43 mg per gram of dry cell weight.ConclusionsA lycopene hyper-producer E. coli strain that does not carry a plasmid or antibiotic marker was constructed using triclosan-induced chromosomal evolution. The methods detailed in this study can be used to engineer E. coli to produce other metabolites.

【 授权许可】

Unknown   
© Chen et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.